Tumor cells can evade the anti-tumor effects of TGF-β by acquiring alterations in the TGF-β signaling pathway, such as mutations in receptors or Smad4 and upregulation of inhibitory Smads [10]. The gene discussed is SMAD4; the disease is neoplasm.